Figure 1
Compounds targeting the two-metal nuclease active site, including the FDA approved HIV integrase inhibitor raltegravir (Isentress)35, along with the first influenza lead compound in this class, L-742,001 (1)46, and several recently developed experimental influenza endonuclease inhibitors (2 17, 3 21, 4 47, and 5 48). The general structure 6 shows the structure of the active inhibitors reported in this publication.
